• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    2/14/24 4:05:33 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMRA alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Enliven Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    29337E102
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,901,816*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,901,816*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,901,816*

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.0%*

     
    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

    *See Item 4 for additional information.

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     
    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,901,816*

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,901,816*

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,901,816*

     
    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.0%*

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

    *See Item 4 for additional information.

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    Item 1. (a) Name of Issuer
       
      Enliven Therapeutics, Inc. (the “Issuer”)
       
    Item 1. (b) Address of Issuer’s Principal Executive Offices
       
      6200 Lookout Road, Boulder, CO 80301
       
    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.
       
    Item 2. (d) Title of Class of Securities
       
      Common Stock, par value $0.001 per share (the “Common Stock”)
       
    Item 2. (e) CUSIP No.:
       
      29337E102
       
    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:
       
      N/A

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    Item 4. Ownership
       
      As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:
       
      (a) Amount Beneficially Owned: 2,901,816*
      (b) Percent of Class: 7.0%*
      (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 2,901,816*
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 2,901,816*

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:
     
    (a) Amount Beneficially Owned: 2,901,816*
    (b) Percent of Class: 7.0%*
    (c) Number of Shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 2,901,816*
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 2,901,816*

     

    *The Firm is the investment manager to Commodore Master. As of December 31, 2023, the Firm may be deemed to beneficially own an aggregate of 2,901,816 shares of Common Stock of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 41,211,973 shares of Common Stock reported as issued and outstanding as of November 1, 2023 in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2023.

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person
       
      Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
       
      Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      Not Applicable.
       
    Item 9. Notice of Dissolution of Group
       
      Not Applicable.
       
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

    1. Joint Filing Agreement dated as of April 24, 2023, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on April 24, 2023).

     

     
     

     

    CUSIP No. 29337E102 SCHEDULE 13G  

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Commodore Capital LP  
       
    By: /s/ Michael Kramarz  
    Michael Kramarz, Managing Partner  
       
    Commodore Capital Master LP  
       
    By: /s/ Michael Kramarz  
    Michael Kramarz, Authorized Signatory  

     

     

     

    Get the next $IMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMRA

    DatePrice TargetRatingAnalyst
    1/6/2022$12.00 → $4.00Equal-Weight
    Morgan Stanley
    11/30/2021$10.00Buy
    HC Wainwright & Co.
    8/11/2021$33.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $IMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

      SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/16/24 4:15:28 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/14/24 8:53:21 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/14/24 4:58:16 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley reiterated coverage on Imara with a new price target

      Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

      1/6/22 10:34:33 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Imara with a new price target

      HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00

      11/30/21 7:23:31 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously

      8/11/21 6:17:27 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    SEC Filings

    See more
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      2/15/24 5:04:57 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      12/20/23 6:06:54 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by IMARA Inc.

      144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

      12/19/23 5:27:50 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • 5am Partners Vi, Llc sold $12,292,500 worth of shares (825,000 units at $14.90) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/16/24 4:15:31 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Phillips Andrew John

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/15/24 9:04:08 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Patel Anish

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      2/15/24 9:02:21 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

      Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele

      11/8/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

      BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical

      6/30/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

      BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia.  “We are exc

      1/20/21 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Imara Announces Stockholder Approval of Merger With Enliven

      -- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. ("Enliven") pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into

      2/22/23 4:01:00 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lifshitz Law PLLC Announces Investigations of IMRA, AGFS, USER, and PEBO

      NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Lifshitz Law PLLC:Imara Inc. (NASDAQ:IMRA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of IMRA and Enliven Therapeutics, Inc.If you are an IMRA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Solutions, Inc. (NASDAQ:AGFS)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AGFS to Paine Schwartz Partners for $3.00 per share in cash.If you a

      11/23/22 7:48:00 PM ET
      $AGFS
      $IMRA
      $PEBO
      $USER
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Major Banks
      Finance
    • Enliven Therapeutics and Imara Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

      10/13/22 4:35:22 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMRA
    Financials

    Live finance-specific insights

    See more
    • Enliven Therapeutics and Imara Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

      10/13/22 4:35:22 PM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara Reports Full Year 2021 Financial Results and Business Highlights

      Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022 Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders Company to host conference call and live webcast today at 8:30 AM ET BO

      3/15/22 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

      BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800

      3/8/22 7:00:00 AM ET
      $IMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care